Published in Cancer Res on January 15, 2002
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol (2007) 1.77
Sympathetic modulation of immunity: relevance to disease. Cell Immunol (2008) 1.33
Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis (2011) 1.28
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer (2003) 1.25
Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol (2007) 1.22
Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res (2006) 1.21
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One (2012) 1.15
Targeting caspases in cancer therapeutics. Biol Chem (2013) 1.13
Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol (2006) 1.04
Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer (2009) 0.94
Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest (2003) 0.93
Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene (2005) 0.91
Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.91
The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression. Oncotarget (2014) 0.89
The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother (2004) 0.88
Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia (2007) 0.86
Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res (2007) 0.85
Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists. Gene Ther Mol Biol (2008) 0.83
5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists. J Comput Aided Mol Des (2013) 0.82
Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. PLoS One (2012) 0.79
Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology (2005) 0.78
The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT. Anticancer Res (2015) 0.77
The antihypertension drug doxazosin suppresses JAK/STATs phosphorylation and enhances the effects of IFN-α/γ-induced apoptosis. Genes Cancer (2014) 0.77
Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells. ScientificWorldJournal (2013) 0.76
The cytotoxicity of the α1-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P. Toxicology (2015) 0.76
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia. Int J Mol Sci (2016) 0.75
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers. Int J Mol Sci (2016) 0.75
The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy. Curr Urol (2017) 0.75
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol (2004) 1.82
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol (2007) 1.77
Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res (2010) 1.74
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer (2008) 1.70
Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J (2009) 1.67
Retracted Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila) (2009) 1.57
Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur Urol (2011) 1.51
Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res (2005) 1.39
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets (2009) 1.25
Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem (2006) 1.22
Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res (2006) 1.21
Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med (2010) 1.19
Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. Int J Cancer (2009) 1.18
Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res (2006) 1.15
Live free or die: tales of homeless (cells) in cancer. Am J Pathol (2010) 1.15
Targeting caspases in cancer therapeutics. Biol Chem (2013) 1.13
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate (2006) 1.13
Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia (2006) 1.09
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol (2003) 1.08
Significance of talin in cancer progression and metastasis. Int Rev Cell Mol Biol (2011) 1.05
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res (2009) 1.04
Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol (2006) 1.04
Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem (2005) 1.02
Prohibitin regulates TGF-beta induced apoptosis as a downstream effector of Smad-dependent and -independent signaling. Prostate (2010) 1.01
Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem (2004) 1.00
Transforming growth factor beta and prostate cancer. Cancer Treat Res (2005) 0.98
TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Prostate (2008) 0.98
Novel targeting of apoptosis pathways for prostate cancer therapy. Curr Cancer Drug Targets (2004) 0.94
EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate (2011) 0.92
Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene (2005) 0.91
Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer. Cancer Res (2014) 0.89
Proteasomal regulation of caspase-8 in cancer cell apoptosis. Apoptosis (2013) 0.89
Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem (2008) 0.89
Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol (2013) 0.89
The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother (2004) 0.88
Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Rev Endocrinol Metab (2011) 0.86
Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment? Naunyn Schmiedebergs Arch Pharmacol (2009) 0.86
Emerging biomarkers of prostate cancer (Review). Oncol Rep (2012) 0.86
Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res (2007) 0.85
Modeling prostate cancer in mice: limitations and opportunities. J Androl (2011) 0.85
Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opin Ther Targets (2011) 0.84
Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Prostate (2002) 0.84
Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res (2004) 0.84
Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists. Gene Ther Mol Biol (2008) 0.83
Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate (2006) 0.82
Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group. Cancer Res (2010) 0.82
Detection of microRNAs in prostate cancer cells by microRNA array. Methods Mol Biol (2011) 0.82
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate (2004) 0.82
Intracellular death platform steps-in: targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. Prostate (2008) 0.82
Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate (2004) 0.81
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol (2014) 0.79
Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review). Oncol Rep (2002) 0.78
Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology (2005) 0.78
Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res (2013) 0.78
Gene fusions find an ERG-way to tumor inflammation. Cancer Biol Ther (2011) 0.77
Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Anticancer Res (2002) 0.77
Molecular signatures in urologic tumors. Int J Mol Sci (2013) 0.75
p27 Stands-up-to-cancer: UPS nuclear service stops. Endocrinology (2013) 0.75
Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int (2012) 0.75